论文部分内容阅读
采用ELISA双抗体夹心法和3H－TdR释放法分别对176例各种肝病患者及36例正常人血清TNFα和sTNFα进行测定。结果发现各种肝病患者血清TNFα和sTNFαR均明显高于正常对照组（P＜0．05），TNFα和sTNFαR呈明显正相关。PHC和CAH患者血清sTNFαR1／sTNFαR2比值明显升高；而MHC和CPH患者血清sTNFαR1/sTNFαR2比值则明显减小（P＜0．05）。疗效较差、病情较重、炎症活动和肿瘤转移时血清TNFα和sTNFαR水平明显升高，提示TNFα参与了肝细胞损伤的病理过程。检测患者血清TNFα和sTNFαR不但能判断病情的严重程度，且能在一定程度上对疾病分期、疗效及预后等做出评估，并为临床诊断和治疗提供有价值的参考指标。
Serum TNFα and sTNFα were measured in 176 patients with various liver diseases and 36 normal controls by ELISA double antibody sandwich method and 3H-TdR release method respectively. The results showed that serum TNFα and sTNFαR in patients with various liver diseases were significantly higher than those in the normal control group (P <0.05), TNFα and sTNFαR were positively correlated. Serum levels of sTNFαR1 / sTNFαR2 in patients with PHC and CAH were significantly higher than those in patients with PHC and CAH, while the ratio of sTNFαR1 / sTNFαR2 in patients with MHC and CPH was significantly decreased (P <0.05). Poor efficacy, serious condition, serum inflammatory cytokines and tumor necrosis TNFα and sTNFαR levels were significantly elevated, suggesting that TNFα involved in the pathological process of liver cell injury. Detecting serum TNFα and sTNFαR can not only judge the severity of the disease, but also evaluate the disease stage, efficacy and prognosis to a certain extent, and provide valuable reference for clinical diagnosis and treatment.